The Corporate Council is a unique partnership opportunity – showcasing a commitment to collaboratively identify and address the needs of people with epilepsy globally.
The Council is composed of a select group of leading companies committed to the cause of epilepsy; by meaningfully engaging with people with epilepsy and their representatives. Members in 2025 are Angelini, Jazz, Sanofi, Stoke, Takeda, UCB, Uniqure, Lundbeck and Biohaven.
Membership is by invitation only, but expressions of interest can be submitted.
Guiding Principles
- Driven by the needs of people with epilepsy
- Independent and Neutral (IBE)
- Collaborative and Non-Competitive
- Jointly Accountable and Collectively Responsible
- Active and Engaged
- Transparent, Inclusive, and Diverse
- Impact Oriented
Why a Corporate Council? Benefits for IBE
- Insight into pipelines and priorities of companies working in the epilepsy space to inform strategic direction and annual work plans
- Route to amplify the voice of people with epilepsy in relevant R&D pathways, ensuring research is designed with the perspectives of people with epilepsy in mind
- Opportunity to access expertise in the research, medical, and regulatory space
- Protecting resources by bringing companies together in one place, rather than exhausting a limited pool of expert patients to engage with companies individually
- Platform for working, stronger and faster, in partnership, on areas of mutual interest for a common cause
- Source of support for ongoing IBE projects and activities, contributing to organisational sustainability
Why a Corporate Council? Benefits for Members
- Opportunity to collaboratively raise awareness of epilepsy, in partnership with IBE – the only global voice for people with epilepsy; with almost 160 chapters in over 110 countries worldwide.
- Possibilities to inform and shape policy, advocacy, and capacity-building initiatives to create an ecosystem in which the burden of epilepsy is recognised and resourced accordingly.
- Access to the perspectives of people with epilepsy globally – which can be used to inform R&D, regulatory and reimbursement processes, etc., including the possibility to aggregate and generate powerful intelligence.
- Early engagement to simplify compliance barriers and overcome bureaucratic internal processes, by priority-setting and co-creating from the outset.
- Platform to showcase commitment to collaboratively identify and address the needs of people with epilepsy globally; leading to enhanced Corporate Social Responsibility and increased visibility across the epilepsy community